Webinars April 7, 2022 AMCP Policy & Government Relations Agenda – 2022 and Beyond AMCP webinar that provided an overview of AMCP's long-term strategic federal legislative agenda. Legislation & Regulation, Biosimilars, Pre-Approval Information Exchange
Resource April 7, 2022 AMCP Policy & Government Relations Agenda – 2022 and Beyond AMCP webinar that provided an overview of AMCP's long-term strategic federal legislative agenda. Biosimilars, Pre-Approval Information Exchange, Legislation & Regulation
Resource April 7, 2022 AMCP Policy & Government Relations Agenda – 2022 and Beyond AMCP webinar that provided an overview of AMCP's long-term strategic federal legislative agenda. Biosimilars, Pre-Approval Information Exchange, Legislation & Regulation
Press Releases December 11, 2018 AMCP CEO Statement on FDA’s Proposed Guidance That Would Reclassify Insulin as a Biologic Press Release: DA’s Proposed Guidance That Would Reclassify Insulin as a Biologic Biosimilars, Government/Legal Affairs, Legislation & Regulation